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Summary 
This follow-up study investigated lymphocyte blastogenesis induced by concanavalin A, phytohemag- 
glutinin A, and pokeweed mitogen and their sensitivity to in vitro dexamethasone administration in 12 
patients clinically recovered from severe major depression. Although cortisol-levels at 4.00 p.m. de- 
creased significantly after clinical remission, mitogen-driven lymphocyte proliferative responses were 
unchanged when assessed intra-individually. No impairment of in vitro glucocorticoid-sensitivity of 
lectin-induced lymphocyte blastogenesis could be observed in clinically recovered patients. The inhibitory 
potency of in vitro dexamethasone was found to be inversely correlated with in vivo adrenal cortical 
hormone levels. There were no correlations with age, weight, sex, antidepressant medication, severity or 
duration of depression. No differences from age- and sex-matched healthy individuals were found. These 
results indicate that reduced glucocorticoid receptor sensitivity occurs only during the acute depressive 
illness. 
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Introduction 
In recent years, research in the field of affec- 
tive disorders has paid much attention to alter- 
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ations in immune system and hypothalamic-pitui- 
tary-adrenai axis CHPA) integrity. Approximately 
50% of patients have been shown to have an 
increased HPA-axis activity during acute depres- 
sive illness, e.g., excess cortisol production and 
resistance to dexamethasone suppression (Carroll 
et al., 1968; Linkowski et al., 1987). Despite this, 
they did not display clinical signs of Gushing’s 
syndrome. This might simply be explained by the 
32 
different duration and magnitude of hypercorti- 
solism. On the other hand, an impaired glucocor- 
ticoid-mediated negative feedback was detected 
with a variety of hormones, e.g., ACTH, P-En- 
dorphin, prolactin, and TSI-I (Fang et al., 1981; 
Rupprecht et al., 1987; 1988; 1989). It was re- 
ported that these neuroendocrine abnormalities 
reverse to normal values after clinical recovery of 
patients with major depression (Linkowski et al., 
1987; Rupprecht et al., 1989). As this derange- 
ment includes different neuroendocrine systems, 
this might indicate a more generalized phe- 
nomenon of putative pathophysiological signifi- 
cance, at least in a subgroup of patients suffering 
from major depressive disorder. Moreover, these 
fundamental neuroendocrine changes should also 
affect immunocompetent cells. 
Glucocorticoids are able to inhibit in vivo and 
in vitro antigen- and mitogen-induced T lympho- 
cyte proliferation and lymphokine production in a 
dose-dependent manner. In contrast, only the 
early activation phase of the B cell cycle is re- 
ported to be sensitive to the suppressive ffects of 
glucocorticoids (Cupps and Fauci, 1982; Bowen 
and Fauci, 1984). 
Therefore, peripheral blood mononuclear cells 
are a suitable tool to study receptor sensitivity 
and the regulatory potency of gb:cocorticoids, 
since these cells possess glucocorticoid receptors 
and are highly sensitive to glucocorticoids (Cupps 
and Fauci, 1982). 
Recently, we reported a decreased sensitivity 
of the lymphocyte glue sorticoid receptor to in 
vitro added dexamethasone in severely depressed 
in-patients (Wodarz et al., 1991). This follow-up 
study in the same cohort of subjects after com- 
plete clinical recovery was designed to address 
the following questions: 
(1) Is the integrity of cell-mediated immunity 
maintained in patients with major depressive dis- 
order (according to DSM-III-R) after complete 
clinical remission, despite the suspected funda- 
mental changes in neuroendocrine regulation. 
(2) Is the impaired glucocorticoid sensitivity of 
lymphocytes in severely depressed patients re- 
versed to normal values after clinical recovery, as 
TABLE 1 
Demographic and clinical data of the 12 clinically recovered patients with major depressive disorder 
age 
(Y) 
XX DSM-III-R HRS-D 
depr. 
HRS-D 
recov. 
duration of 
treatment 
(davs) 
medication 
recov. 
44 F 296.53 33 !O 75 
66 F 296.33 36 10 28 
61 F 296.34 28 9 24 
64 F 296.33 28 I 125 
39 F 296.33 25 2 30 
60 M 295.33 24 1 30 
60 M 296.33 28 9 90 
34 F 296.33 28 10 89 
54 F 296.53 33 1 28 
18 F 296.23 26 4 28 
53 M 296.33 26 5 30 
34 F 296.33 39 6 95 
48.1 
f 15.1 
29.5 
* 4.7 
5.7 
+ 1.1 
56 
f 10.4 
100 mg ami 
480 mg nor 
100 mg cl0 
600 mg lit 
200 mg ami 
150 mg ami 
175 mg ami 
75 mg cl0 
75 mg ami 
!75 mg ami 
20 mg tra 
200 mg ami 
Mean 
*SD 
Age (years), sex (F = female; M = male), DSM-III-R (3rd revised version of the diagnostic and statistical manual of the American 
Psychiatric Association), HRS-D (score on the 21-item Hamilton Rating Scale for Depression; depr. = depressed, recov. = 
recovered). medication (ami = amitryptiline; nor = nortryptiiine; clo = clomipramine; lit = lithium; tra = tranylcypromine). 
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it has been reported for other neuroendocrine 
abnormalities. 
(3) Are the results associated with circulating 
concentrations of adrenal cortical hormones, such 
as cortisol and ACTH. 
(4) Are the results affected by pharmacological 
treatment, duration of illness or several other 
variables, such as gender, age, and weight? 
Subjects and Methods 
Subjects 
12 subjects (mean age + SD: 48.7 + 15.1 years; 
mean body weight + SD: 72.5 f 13.4 kg), admit- 
ted to the psychiatric clinic of the University of 
Wiirzburg with severe unipolar major depressive 
disorder or bipolar depression (according to 
DSM-III-R) and 13 non-hospitalized healthy con- 
trols, closely matched for age, sex and weight 
(mean age f SD: 47.4 + 6.4 years; mean body 
weight + SD: 69.2 + 8.6 kg) were studied (for de- 
mographic and clinical data see Table I). The 
severely depressed patients were investigated 
during the first week after admission to the hos- 
pital (Wodarz et al., 1991). They were re-investi- 
gated after complete clinical recovery. 4 female 
depressives and the matched controls were tested 
during the midluteal phase of the cycle, the other 
females were postmenopausal. 
All subjects were carefully screened for nutri- 
tional status and prevalence of medical illness, as 
well as alcohol or nicotine abuse and stressful ife 
events that might influence pituitary-adrenal or 
immune system integrity by medical history, phys- 
ical examination and routine laboratory investiga- 
tion. 
All patients had clinically recovered at the 
time of this investigation and received pharmaco- 
logical treatment (Table 1). DSM-III-R (Ameri- 
can Psychiatric Association, 1987) diagnoses were 
made independently by two psychiatrists, who 
were blind to laboratory investigations. Severity 
of depression was assessed on the day of labora- 
tory investigations using the 21-item Hamilton 
Rating Scale for Depression (HRS-D; Hamilton, 
1960). 
Controls had no history of psychiatric disorder, 
nor relatives exhibiting psychiatric illness. They 
were free of any medication and their HRS-D 
scores were below 5. 
Written informed consent was obtained from 
all subjects prior to the investigation. This study 
was approved by the ethical committee of the 
University of Wiirzburg. 
Assays 
All subjects were admitted to a sleep tabora- 
tory unit at least one hour prior to blood sam- 
pling. For determination of hormonat values and 
cell-mediated immunity measurements, 50 ml ve- 
nous blood were collected at 4.00 p.m. into plas- 
tic tubes containing EDTA. 
Preparation of ceils 
Peripheral blood mononuclear cells (PBMC) 
were prepared from EDTA-blood under sterile 
conditions by sodium metrizoate-Ficoll density 
gradient centrifugation as described previously in 
detail (Wodarz et al., 1991). Viability of cells 
always exceeded 95%, as judged from their ability 
tc, exclude trypan blue (Pappenheimer, 1917). 
Contamination by granulocytes and monocytes 
was always less than 8%. 
Cell culture 
Cell cultures were performed exactly as de- 
scribed previously in detail (Wodarz et al., 1991). 
Briefly, PBMC were suspended at a concentra- 
tion of 2.5 X 104/well in culture medium (see 
details under heading Chemicals) and incubated 
in triplicate in 96-well microtiter plates (0.2 
ml/well; NUNC, Sweden) for 60 h to evaluate 
Con A- and PHA-generated T cell proliferation 
and for 132 h to evaluate PWM-generated acces- 
sory cell-dependent B cell proliferation in a ster- 
ile, humidified atmosphere (5% CO,/95% air). 
To assess in vitro glucocorticoid sensitivity, lo- “’ 
to 10mh mol/l dexamethasone (DEX) were added 
to spontaneous (without lectin) and mitogen- 
driven lymphocyte cultures. One optimum and 
one non-optimum concentration of each lectin 
was used for mitogen-driven lymphocyte cultures. 
To measure DNA-synthesis 0.5 &i 13Hlthymi- 
dine were added 5 h prior to termination of the 
incubation period. Incorporation of 13Hlthymi- 
dine was assessed by rapid filtration through 
Whatman GF/B filters (Whatman, Maidstone, 
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G.B.). The radioisotope was measured by a stan- 
dard liquid scintillation count in a Beckman LS 
5000 TD counter at about 54% efficiency. All 
samples were assayed in triplicate. The coeffi- 
cient of variation was always less than 16%. 
Serum hormone determinations 
_4CTH was measured by a newly developed 
immunoradiometric assay (IRMA) supplied by 
the Nichols Institute (San Juan Capistrano, CA 
Raff and Findling, 1989). The lower detection 
limit was 1.5 pmol/l, and the intra- and interas- 
say coefficients of variation were 3% and 6.8%, 
respectively. Cortisol was measured by a direct 
radioimmunoassay (RIA; Stalla et al., 1981). The 
lower detection limit was 25 nmol/l, and the 
intra- and interassay coefficients of variation were 
5% and 9%, respectively. 
Chemicals 
[ 3H]Thymidine was obtained from Amersham, 
G.B. Phosphate rl b fcered saline (PBS) was ob- 
tained from Boehringer (Mannheim, F.R.G.). 
Concanavalin A (Con A), phytohemagglutinin .4 
(PI-IA), pokeweed mitogen (PWM), dexametha- 
sane and sodium metrizoate-Ficoll were obtained 
from Sigma (St. Louis, MO), and Rotiszint 22 was 
obtained from Roth (Karlsruhe, F.R.G.). Con A, 
PI-IA, PWM and dexamethasone were diluted to 
the respective final concent -*ions with culture 
medium. The culture medium consisted of 
Rosewell Park Memorial Institute Medium 
(RPMI) 1640 (Boehringer, Mannheim, F.R.G.) 
supplemznted with 2 mM L-glutamate (Bio- 
chrom, Berlin), 0.1 mg/ml gentamycine (Bio- 
chrom, Berlin, F.R.G.) and 10% fetal calf serum 
(FCS, Biochrom, Berlin, F.R.G.). The same lots 
of lectins and FCS were used throughout the 
whole investigation to limit methodological varia- 
tions. 
Statistical analysis 
Lymphocyte proliferation was expressed in 
terms of a stimulation index (SI) defined by the 
ratio stimulated (in the presence of lectin) counts 
per minute (CPM) divided by spontaneous (in the 
absence of lectin) CPM. The results are mean 5 
SD, except where otherwise stated. Hormone val- 
ues below the detection limit of our assays were 
recorded as the respective detection limits. Data 
TABLE 2 
Hormone values and lymphocyte proliferative responses of patients with major depressive disorder and controls 
Cortisol: 
ACl-H: 
Controls 
N=13 
225.7 f 77.3 
3.6f 0.8 
Patients Patients 
depr. recob. 
N=12 N=12 
273.1+ 104.8 194.3 * 77.9 nmol/l 
4.2+ 1.5 4.6 + 1.9 pmol/l 
optimum 
10.0 pg/ml PHA: 
10.0 kg/ml Con A: 
10.0 pg/ml PWM: 
non-optimum 
1.0 kg/ml PHA: 
1.0 pg/ml Con A: 
1.0 pg/ml PWM: 
stimulation Indices 
28.05 5.0 
15.1+ 2.4 
17Sf 3.1 
9.2+ 1.4 
5.6+ 0.9 
11.7+ 2.4 
23.4f 3.9 18.9+ 4.2 
14.7* 2.1 17.9* 3.1 
21.9+ 4.2 17.?+ 6.3 
9.4f 1.6 8.9f 1.7 
4.0+ 0.5 4.8* 0.6 
15.9+ 2.7 11.9* 4.6 
The meanf SD hormone values are expressed in pmol/l and the mean f 0’1 lymphocyte proliferative responses by terms of a 
stimulation index [defined by the ratio stimulated (in the presence of lectin) counts per minute (CPM) vs. spontaneous (in the 
absence of lectin) CPM]; phytohemagglutinin A (PHA); Concanavalin A (Con A); pokeweed mitogen (PWM). Cortisol-values at 
4.00 p.m. decreased significantly intra-individually in patients with major depression after clinical recovery 0’ < 0.05). The results 
obtained during the acutely depressed state vs. control subjects were discussed in detail in a previous report (Wodarz et al., 1991). 
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were analyzed using Pearson’s product-moment 
correlation, t-test for dependent variables, and 
analysis of covariance (ANCOVA). All signifi- 
cance levels are two-tailed. 
Results 
Cell uiability 
Under culture conditions of the lymphocyte 
proliferation assay, the mean cell viabilities at the 
time of harvest (day 3 and day 5) were 96.8% Z?I 
1.4% and 94.9% f 2.5%, respectively. 
Descriptive statistics 
Table 1 surnmarrzes important demographic 
and clinical data of the 12 patients studied after 
clinical recovery. There were no significant differ- 
ences in age, weight and hormone values between 
the control and patient group. Patients with ma- 
jor depressive disorder exhibited significantly de- 
creased cortisoLvalues at 4.00 p.m, after clinical 
recovery (t = 2.31; P < 0.09, whereas ACTH-val- 
ues did not change significantly. 
No significant correlations could be seen be- 
tween age, weight, HRS-D score, duration of 
treatment, medication and hormone values. Cor- 
tisol- and ACTH-values were significantly corre- 
lated in recovered patients (r = - 0.65, P = 0.024, 
N = 121, but not in the same patients suffering 
from acute depressive illness (r - 0.38, P = 0.24, 
N = 12). 
Lectin-induced Iymphocyte blastogenesis 
Table 2 shows the hormone values and the 
lymphocyte proliferative responses after stimula- 
tion with one optimum and one non-optimum 
concentration of each lectin. Blastogenesis clid 
not differ significantly between healthy individu- 
als and patients, irrespective of the lectin and the 
concentration used. 
No significant correlations could be observed 
between lymphocyte responses to PWM, Con A 
or PHA and age, weight, HRS-D score or corti- 
sol-values. only PHA-induced lymphocyte blasto- 
genesis was significantly associated with cortisol- 
values at 4.00 pm. in recovered patients (Table 3). 
No significant imfluence of treatment with tri- 
cyclic antidepressants could be detected. 
% of basal proliferation 
I 
IOO- 
75- 
50- 
25- 
0' _. _-- 
lE-10 lE-9 lE-8 IE-7 lE-6 
- - dexamethaaone [MI 
Fig. 1. Effect of 10-‘“-lO-” M in vitro dexamethasone on 1.0 
pg/ml PHA-induced lymphocyte blastogenesis (arithmetic 
means, not adjusted for in vivo cortisol; standard deviations 
(SD) were omitted for reasons of clarity). Even after covarying 
out serum cortisollevels, the differences between healthy con- 
trols (N = 13) and recovered patients (N = 12) were not statis- 
tically significant. The rcs& obtained during the acutely 
depressed sta!e vs. sont~G suqcts were discussed in detail in 
a previous report il’flodan et al., 1991). 
Sensitivity of ,>mphocyte proliferation ts +I vitro 
added denamethasone 
In vitro administration of DEX produced a 
dose-dependent decrease of spontaneous, PHA- 
(Fig. 1) and Con A-induced T-lymphocyte prolif- 
erative responses (Fig. 2) in healthy controls and 
patients. No suppressive ffects of DEX could be 
96 of basal proliferation 
125- 
loo- $?-____ 
75- 
50 
I 
-t depr. Pat. 
25 
1 
0’ 
lE-10 lE-9 lE-8 lE-7 IE-6 
dexamethasone [MI 
Fig. 2. Effect of lo-‘“-lo-” M in vitro dexamethasone on 1.0 
pg/ml Con A-induced lymphocyte blastogenesis (arithmetic 
means, not adjusted for in vivo cortisol; SD were omitted for 
reasons of clarity). The differences between healthy controls 
(N = 13) and recovered patients (N = 12) were not statistically 
significant. The results obtained during the acutely depressed 
state vs. control subjects were discussed in detail in a previous 
report (Wodarz et al., 1991). 
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I 
-iE-10 IE-9 IE-8 lE-7 IE-6 
dexamethasone bll 
Effect of 10-l”-lO-h M in vitro dexamethasone on 
10.0 fig/ml PWM-induced lymphocyte blastogenesis (arith- 
metic means, not adjusted for in vivo cortisol; SD were 
omitted for reasons of clarity). The differences between 
healthy controls (N= 13) and recovered patients (N= 12) 
were not statistically significant, The results obtained during 
the acutely depressed state vs. control subjects were discussed 
in detail n a previous report (Wodarz et al., 1991). 
observed on PWM-driven ar:essory cell-depen- 
dent B-cell blastogenesis in all individuals (Fig. 
3). The inhibitory potency of in vitro DEX on 
PHA-induced T-cell proliferation was signifi- 
cantly associated with serum cortisol-levels at 4.00 
p.m. in recovered patients (Table 3). 
No significant correlations could be observed 
between in vivo levels of adrenal cortical hor- 
mones and the DEX-induced inhibition of cells 
TABLE 3 
Correlations between in vivo cortisol-levels and in vitro sensi- 
tivity of phastimulated lymphocyte blastogenesis to dexam- 
ethasone in recovered patients with major depressive disorder 
DEX 
hol/ll 
1.0 pg/ml 10.0 pg/ml PHA 
Cortisol Cortisol 
without -0.77 * - 0.64 ’ 
lo-‘0 -0.79 * -0.84 ** 
1o-9 -0.75 * -0.82 ** 
10-s -0.75 * -0.81 ** 
10-7 - 0.64 a -0.84 ** 
10-6 -0.45 -0.78 * 
N = 12; dexamethasone [mol/llr correlation coefficient r; 
**P<o.oos; *P<o.o5;“P<o.l; 
stimulated with optimum or non-optimum con- 
centrations of Con A and PWM. Since a signifi- 
cant association of in vivo hormone levels and in 
vitro PI-IA-driven T-blastogenesis could be estab- 
lished (Table 3), it seemed useful to examine this 
statistically. An analysis of covariance adjusted 
the individuals’ in vitro lymphocyte proliferation 
for the respective in vivo hormone values, i.e., 
covaried out the infIuence of in vivo hormone 
levels. Nevertheless, there were no significant dif- 
ferences in DEX-sensitivity of spontaneous, 
PWM-, PHA- and Con A-stimulated lymphocytes 
between healthy individuals and recovered pa- 
tiects with major depressive disorder. 
Discussion 
We recently reported that PHA-stimulated T- 
lymphocytes of severely depressed in-patients ex- 
hibited a significantly decreased sensitivity to in 
vitro dexamethasone (Wodarz et al., 1991). This 
follow-up in the same cohort of subjects demon- 
strates that the impaired lymphoqte glucocorti- 
coid sensitivity is reversed to normal values after 
clinical recovery of patients with major depressive 
disorder. Other abnormalities in neuroendocrine 
regulation were also reported to be state depen- 
dent, e.g., 24-hour hypersecretion of cortisol and 
the disturbed response to dexamethasone (Lin- 
kowski et al., 1987; Rupprecht et al., 1989). 
Our severely depressed patients tended to have 
higher cortisol-levels than healthy individuals 
(Wodarz et al., 1991). There was a significant 
decrease of cortisol-levels at 4.00 pm. intra-indi- 
vidually after clinical recovery. Nevertheless, the 
association between in vitro glucocorticoid sensi- 
tivity of PHA-driven T-blastogenesis and in vivo 
cortisol levels at 4.00 p.m. persisted in recovered 
patients. Moreover, the missing correlation of 
ACTH and cortisol during the depressed state 
could be observed again after clinical recovery. 
Since lymphocyte glucocorticoid receptor den- 
sity was found to be unchanged in depressed 
patients (Schlechte and Sherman, 1985; Rup- 
precht et al., 19911, our results might further 
support the hypothesis of a glucocorticoid recep- 
tor dysfunction in patients with major depressive 
disorder. 
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Lowy et al. (1988) have also described a weaker 
DEX-induced suppression of lymphocyte blasto- 
genesis, but only after stimulation with Con A. 
This discrepancy might be mainly attributed to 
methodological differences (e.g., time of blood 
sampling and concentrations of lectins), as well as 
differences in selection criteria of patients (e.g., 
dexamethasone suppressors and non-suppres- 
sors). But it has to be noticed that both observa- 
tions point in the same direction. However, Lowy 
et al. (1988) did not perform a follow-up in their 
patients after clinical recovery. 
Studies on the integrity of cell-mediated im- 
munity in patients with major depressive disorder 
have been inconsistent. Some groups reported 
normal in vitro lymphocyte responses to the 
lectins Con A, PHA and PWM (Albrecht et al., 
19S5; Lowy et al., 1988; Darko et al., 1989; 
Schleifer et al., 19891, whereas others found a 
significantly decreased (Kronfol et al., 1986; Cal- 
abrese et al., 1987; Cosyns et al., 1989; Levy et al., 
1991) or even increased response (Altshuler et 
al., 1989) to some lectins in depressed patients 
compared to various control groups. 
All these groups did not re-investigate patients 
after clinical improvement. Therefore, this fol- 
low-up study re-investigated a cohort of subjects 
with major depressive disorder, who exhibited no 
significant disturbance in the lymphocyte trans- 
formation test during severe depressive illness 
(Wodarz et al., 1991). We could not demonstrate 
any significant differences in lectin-induced T- 
and B-lymphocyte blastogenesis between the 
severely depressed and clinically recovered state. 
Moreover, there were no differences to this 
measure of cell-mediated immunity in age- and 
sex-matched healthy individuals. 
The above cited studies differed quite consid- 
erably in the methodology applied (e.g., concen- 
trations of lectins, incubation period), as well as 
selection criteria of patients (e.g., diagnostic cri- 
teria, severity of depression, medication, age, sex), 
as discussed previously in detail (Wodarz et al., 
1991). 
We were not able to establish an association 
between lectin-induced lymphocyte blastogenesis 
and factors like age, gender or weight in our 
clinically recovered patients. This is in accor- 
dance with previous work (Albrecht et al., 1985; 
Kronfol et al., 1986; Cosyns et al., 1989) and our 
own results (Wodarz et al., 1991) during the de- 
pressive syndrome. 
Moreover, we could not observe a correlation 
between in vitro lymphocyte blastogenesis and in 
vivo levels of adrenal cortical hormones in our 
recovered patients. This is in accordance with 
results in other laboratories (Dark0 et al., 1989; 
JGronfol and House, 1989; Schleifer et al., 1989) 
and our own findings during the depressed state 
(Wodarz et al., 1991). 
There were no significant effects of antide- 
pressant medication, duration of treatment or 
number of depressive episodes on lectin-induced 
lymphocyte proliferative responses. 
Despite the variety of fundamental changes in 
neuroendocrine regulation during the acute de- 
pressed state and after complete clinical recovery, 
the integrity of cell-mediated immunity could ob- 
viously be maintained in patients with major de- 
pressive disorder. But the impaired in vitro gluco- 
corticoid sensitivity of PHA-induced T-cell blas- 
togenesis during acute depressive illness may in- 
dicate that this fragile homeostasis might be diffi- 
cult to maintain, if additional disturbances occur 
(e.g., pharmacological induced, as well as physio- 
logical, shifts in hormonal balance). 
Further analysis of glucocorticoid receptor 
functionality (e.g., by means of in vivo and in vitro 
chal!enge studies) should be performed to define 
the pathopbysiological relevance of the state-de- 
pendent impaired receptor sensitivity in patients 
with major depressive disorder. 
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